Long-term administration of Rho-kinase inhibitor ameliorates renal damage in malignant hypertensive rats

Hypertension

Volumn 47, Issue 6, 2006, Pages 1075-1083

  Ishikawa, Yayoi ^a   Nishikimi, Toshio ^a   Akimoto, Kazumi ^a   Ishimura, Kimihiko ^a   Ono, Hidehiko ^a   Matsuoka, Hiroaki ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Deoxycorticosterone; Extracellular matrix; Glomerusclerosis; Hypertension, malignant; Kinase; Oxidative stress; Transforming growth factors

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; DEOXYCORTICOSTERONE ACETATE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FASUDIL; MESSENGER RNA; PROTEIN P40; PROTEIN P47; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RHO KINASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; 1 (5 ISOQUINOLINESULFONYL) 2 METHYLPIPERAZINE; 8 EPI PROSTAGLANDIN F2ALPHA; 8-EPI-PROSTAGLANDIN F2ALPHA; DEOXYCORTICOSTERONE; DRUG DERIVATIVE; ECTODYSPLASIN A; ISOPROTEIN; MEMBRANE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; PROSTAGLANDIN F2 ALPHA; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RHO KINASE; RHO-ASSOCIATED KINASE; SIGNAL PEPTIDE; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CELL INFILTRATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOLOGY; KIDNEY CORTEX; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY MASS; LONG TERM CARE; MACROPHAGE; MALE; MALIGNANT HYPERTENSION; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEINURIA; RAT; RAT STRAIN; RENAL PROTECTION; SPONTANEOUSLY HYPERTENSIVE RAT; UPREGULATION; ANIMAL; CHEMICALLY INDUCED DISORDER; DRUG ADMINISTRATION; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOHISTOCHEMISTRY; KIDNEY; METABOLISM; PATHOLOGY; URINE; WISTAR KYOTO RAT;

1-(5-ISOQUINOLINESULFONYL)-2-METHYLPIPERAZINE; ANIMALS; DESOXYCORTICOSTERONE; DINOPROST; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECTODYSPLASINS; GENE EXPRESSION; HYPERTENSION, MALIGNANT; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY; KIDNEY CORTEX; MEMBRANE PROTEINS; NADP; NITRIC OXIDE SYNTHASE TYPE III; PROTEIN ISOFORMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; RATS; RATS, INBRED SHR; RATS, INBRED WKY; TUMOR NECROSIS FACTORS;

EID: 33744996300     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000221605.94532.71     Document Type: Article

References (32)

1. Takai Y, Sasaki T, Matozaki T. Small GTP-binding proteins. Physiol Rev. 2001;81:153-208.
2. Fukata Y, Amano M, Kaibuchi K. Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of non-muscle cells. Trends Pharmacol Sci. 2001;22:32-39.
3. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
4. Shimokawa H, Hiramori K, Iinuma H, Hosoda S, Kishida H, Osada H, Katagiri T, Yamauchi K, Yui Y, Minamino T, Nakashima M, Kato K. Anti-anginal effect of fasudil, a Rho-kinase inhibitor, in patients with stable effort angina: a multicenter study. J Cardiovasc Pharmacol. 2002;40:751-761.
5. Nagatoya K, Moriyama T, Kawada N, Takeji M, Oseto S, Murozono T, Ando A, Imai E, Hori M. Y-27632 prevents tubulointerstitial fibrosis in mouse kidneys with unilateral ureteral obstruction. Kidney Int. 2002;61:1684-1695.
6. Satoh S, Yamaguchi T, Hitomi A, Sato N, Shiraiwa K, Ikegaki I, Asano T, Shimokawa H. Fasudil attenuates interstitial fibrosis in rat kidneys with unilateral ureteral obstruction. Eur J Pharmacol. 2002;455:169-174.
7. Nishikimi T, Akimoto K, Wang X, Mori Y, Tadokoro K, Ishikawa Y, Shimokawa H, Ono H, Matsuoka H. Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats. J Hypertens. 2004;22:1787-1796.
8. Kanda T, Wakino S, Hayashi K, Homma K, Ozawa Y, Saruta T. Effect of fasudil on Rho-kinase and nephropathy in subtotally nephrectomized spontaneously hypertensive rats. Kidney Int. 2003;64:2009-2019.
9. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nat Rev Mol Cell Biol. 2003;4:446-456.
10. Higashi M, Shimokawa H, Hattori T, Hiroki J, Mukai Y, Morikawa K, Ichiki T, Takahashi S, Takeshita A. Long-term inhibition of Rho-kinase suppresses angiotensin II-induced cardiovascular hypertrophy in rats in vivo: effect on endothelial NAD(P)H oxidase system. Circ Res. 2003;93:767-775.
11. Wolfrum S, Dendorfer A, Rikitake Y, Stalker TJ, Gong Y, Scalia R, Dominiak P, Liao JK. Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection. Arterioscler Thromb Vasc Biol. 2004;24:1842-1847.
12. Mori Y, Nishikimi T, Kobayashi N, Ono H, Kangawa K, Matsuoka H. Long-term adrenomedullin infusion improves survival in malignant hypertensive rats. Hypertension. 2002;40:107-113.
13. Hattori T, Shimokawa H, Higashi M, Hiroki J, Mukai Y, Tsutsui H, Kaibuchi K, Takeshita A. Long-term inhibition of Rho-kinase suppresses left ventricular remodeling after myocardial infarction in mice. Circulation. 2004;109:2234-2239.
14. 2+ sensitization of prostaglandin F(2α)-induced contraction of rabbit aortae. J Physiol. 2003;546:823-836.
15. Nishikimi T, Mori Y, Kobayashi N, Tadokoro K, Wang X, Akimoto K, Yoshihara F, Kangawa K, Matsuoka H. Renoprotective effect of chronic adrenomedullin infusion in Dahl salt-sensitive rats. Hypertension. 2002;39:1077-1082.
16. Nishikimi T, Tadokoro K, Mori Y, Wang X, Akimoto K, Yoshihara F, Minamino N, Kangawa K, Matsuoka H. Ventricular adrenomedullin system in the transition from LVH to heart failure in rats. Hypertension. 2003;41:512-518.
17. Nishikimi T, Horio T, Sasaki T, Yoshihara F, Takishita S, Miyata A, Matsuo H, Kangawa K. Cardiac production and secretion of adrenomedullin are increased in heart failure. Hypertension. 1997;30:1369-1375.
18. DePasquale MJ, Ringer LW, Winslow RL, Buchholz RA, Fossa AA. Chronic monitoring of cardiovascular function in the conscious guinea pig using radio-telemetry. Clin Exp Hypertens. 1994;16:245-260.
19. Komatsu K, Frohlich ED, Ono H, Ono Y, Numabe A, Willis GW. Glomerular dynamics and morphology of aged spontaneously hypertensive rats. Effects of angiotensin-converting enzyme inhibition. Hypertension. 1995;25:207-213.
20. Ono H, Saitoh M, Ono Y, Ishimitu T, Matsuoka H. Imidapril improves L-NAME-exacerbated nephrosclerosis with TGF-β 1 inhibition in spontaneously hypertensive rats. J Hypertens. 2004;22:1389-1395.
21. Shimosawa T, Shibagaki Y, Ishibashi K, Kitamura K, Kangawa K, Kato S, Ando K, Fujita T. Adrenomedullin, an endogenous peptide, counteracts cardiovascular damage. Circulation. 2002;105:106-111.
22. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K. Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol. 2000;279:H3031-H3039.
23. Adnane J, Seijo E, Chen Z, Bizouarn F, Leal M, Sebti SM, Munoz-Antonia T. RhoB, not RhoA, represses the transcription of the transforming growth factor β type II receptor by a mechanism involving activator protein 1. J Biol Chem. 2002;277:8500-8507.
24. Hubchak SC, Runyan CE, Kreisberg JI, Schnaper HW. Cytoskeletal rearrangement and signal transduction in TGF-β1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol. 2003;14:1969-1980.
25. Border WA, Noble NA. Cytokines in kidney disease: the role of transforming growth factor-β. Am J Kidney Dis. 1993;22:105-113.
26. Horwitz AR, Parsons JT. Cell migration-movin' on. Science. 1999;286:1102-1103.
27. Eddy A. Role of cellular infiltrates in response to proteinuria. Am J Kidney Dis. 2001;37:S25-S29.
28. Iglesias-De La Cruz MC, Ruiz-Torres P, Alcami J, Diez-Marques L, Ortega-Velazquez R, Chen S, Rodriguez-Puyol M, Ziyadeh FN, Rodriguez-Puyol D. Hydrogen peroxide increases extracellular matrix mRNA through TGF-β in human mesangial cells. Kidney Int. 2001;59:87-95.
29. Lassegue B, Griendling KK. Reactive oxygen species in hypertension; An update. Am J Hypertens. 2004;17:852-860.
30. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T, Welch WJ, Wilcox CS. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension. 2002;39:269-274.
31. Mezzetti A, Cipollone F, Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res. 2000;47:475-488.
32. Klahr S. The role of nitric oxide in hypertension and renal disease progression. Nephrol Dial Transplant. 2001;16(suppl 1):60-62.